Corrigendum to “New therapies towards a better glycemic control in youths with type 1 diabetes” [Pharmacol. Res. 2023 Aug 3;195:106882]

Corrigendum to “New therapies towards a better glycemic control in youths with type 1 diabetes” [Pharmacol. Res. 2023 Aug 3;195:106882]

Bibliographic Details
Main Authors:	Roque Cardona-Hernandez, Klemen Dôvc, Torben Biester, Laya Ekhlaspour, Maddalena Macedoni, Martin Tauschmann, Chiara Mameli
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Pharmacological Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661824000537

Similar Items

New therapies towards a better glycemic control in youths with type 1 diabetes
by: Roque Cardona-Hernandez, et al.
Published: (2023-09-01)

Erratum to “Age-related macular degeneration (AMD) is a detrimental eye disease, and the most common cause of visual loss in many countries around the world” [Pharmacol. Res. 208 (2024) 107402]
by: Torben Lykke Sørensen
Published: (2024-12-01)

Erratum to “CD31 orchestrates metabolic regulation in autophagy pathways of rheumatoid arthritis” [Pharmacol. Res. 207 (2024) 107346]
by: Kenneth CP Cheung, et al.
Published: (2024-10-01)

Corrigendum to “Palmitoylethanolamide and Polydatin combination reduces inflammation and oxidative stress in vascular injury” [Pharmacol. Res. 123 (2017) 83–92]
by: Enrico Gugliandolo, et al.
Published: (2024-03-01)

Corrigendum to ‘Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease’ [Pharmacol Res. 174 (2021) 105973]
by: Sudhir Kshirsagar, et al.
Published: (2024-04-01)

Corrigendum to “Ibuprofen-arginine generates nitric oxide and has enhanced anti-inflammatory effects” [Pharmacol. Res. 60 (2009) 159–169]
by: Clara De Palma, et al.
Published: (2023-12-01)

Corrigendum to “Future directions for the discovery of natural product-derived immunomodulating drugs: An IUPHAR positional review” [Pharmacol. Res. 177 (2022) 106076]
by: Cherry L. Wainwright, et al.
Published: (2022-06-01)

Corrigendum to ‘Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein’ [Pharmacol. Res. 175 (2022) 105975]
by: Gamal Eldein Fathy Abd-ellatef, et al.
Published: (2023-03-01)

Corrigendum to “Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity” [Pharmacol. Res. (2020) 152 104586]
by: Tao Su, et al.
Published: (2023-07-01)

Prognosis and Biological Function of miR-3195 in Non-Small Cell Lung Cancer
by: Lu Y, et al.
Published: (2022-01-01)

Erratum to the ‘Long non-coding RNAs-sphingolipid metabolism nexus: Potential targets for cancer treatment’ Pharmacol. Res. 210 (December) (2024) 107539
by: Yan Chen, et al.
Published: (2025-02-01)

Corrigendum to “Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis” [Pharmacol. Res. 173 (2021) 105882]
by: Thawatchai Khuanjing, et al.
Published: (2024-05-01)

Corrigendum to “A novel HIF2A mutation causes dyslipidemia and promotes hepatic lipid accumulation” [Pharmacol. Res. 194 (2023) 106851]
by: Feiqiong Gao, et al.
Published: (2024-04-01)

Prognosis and Biological Function of miR-3195 in Non-Small Cell Lung Cancer [Retraction]
by: Lu Y, et al.
Published: (2023-11-01)

miR-3195 suppresses the malignant progression of osteosarcoma cells via targeting SOX4
by: Jianwei Liang, et al.
Published: (2023-10-01)

Corrigendum to “Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors” [Pharmacol. Res. 210 (2024) 107506]
by: Yuxin Chen, et al.
Published: (2025-03-01)

Erratum to “Cardiovascular disease: Mitochondrial dynamics and mitophagy crosstalk mechanisms with novel programmed cell death and macrophage polarisation” [Pharmacol Res 206 (2024) 107258]
by: Dandan Liu, et al.
Published: (2024-12-01)

Corrigendum to “Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): Current status and future perspectives” [Pharmacol. Res. 209 (2024) 107469]
by: Jinlan Jiao, et al.
Published: (2024-12-01)

Corrigendum to “ACOX1 deficiency-induced lipid metabolic disorder facilitates chronic interstitial fibrosis development in renal allografts” [Pharmacol. Res. 201 (2024) 107105]
by: Yang-He Zhang, et al.
Published: (2024-05-01)

Corrigendum to “Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis” [Pharmacol. Res. 188 (2023) 106668]
by: Tianyao Lei, et al.
Published: (2023-10-01)

Corrigendum to “Novel deoxyhypusine synthase (DHPS) inhibitors target hypusination-induced vasculogenic mimicry (VM) against malignant melanoma” Pharmacol. Res. 209 (November) (2024) 107453
by: Xi-he Zhao, et al.
Published: (2024-12-01)

Corrigendum to “GPR37 promotes cancer growth by binding to CDK6 and represents a new theranostic target in lung adenocarcinoma”[Pharmacol. Res. 183 (2022) 106389]
by: Xiaona Xie, et al.
Published: (2024-10-01)

Corrigendum to “α-Lipoic acid prevents senescence, cell cycle arrest, and inflammatory cues in fibroblasts by inhibiting oxidative stress” [Pharmacol. Res. 141 (2019) 214–223]
by: Maryam Baeeri, et al.
Published: (2024-09-01)

Corrigendum to: An account on the history of pharmacology in Spain [Pharmacol. Res. 202 (2024) 107104 Pages 1–11 https://doi.org/10.1016/j.phrs.2024.107104]
by: Ana María Aldea-Perona, et al.
Published: (2024-07-01)

Corrigendum to “Dihydroartemisinin ameliorates retinal vascular dysfunction in diabetes mellitus via the FASN/Kmal-mTOR/SREBP1 feedback loop” [Pharmacol. Res. 174 (2021) 105871]
by: Chufeng Gu, et al.
Published: (2022-09-01)

Retraction notice to “Myoinositol supplementation for the prevention of gestational diabetes in at-risk patients. Systemativ review and meta-analysis” [Curr. Res. Pharmacol. Drug Discov. 4C (2023) 100140]
by: Anthéa Bertrand, et al.
Published: (2023-01-01)

Day of Surgery Admission in Total Joint Arthroplasty: Why Are Surgeries Cancelled? An Analysis of 3195 Planned Procedures and 114 Cancellations
by: David M. Dalton, et al.
Published: (2016-01-01)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
by: Carolina Schinke, et al.
Published: (2019-03-01)

Corrigendum to “Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis” [Pharmacol. Res. 2022 Sep:183:106376]
by: Liwen Ren, et al.
Published: (2024-07-01)

MÃTODOS INTERPRETATIVISTAS EM ADMINISTRAÃÃO: IMPLICAÃÃES PARA PESQUISADORES
by: Paulo Roberto Maisonnave, et al.
Published: (2010-03-01)

CONSIDERAÃÃES SOBRE USOS E APLICAÃÃES DA GROUNDED THEORY EM ADMINISTRAÃÃO
by: Ana Akemi Ikeda, et al.
Published: (2009-06-01)

3195 A case report of acute disseminated encephalomyelitis with prominent meningeal involvement and benefit from delayed plasma exchange therapy
by: Michael Barnett, et al.
Published: (2024-08-01)

Sobre la composición del Canzoniere (codice Vat. lat. 3195): sistema de peticiones, macrosecuencias y sesquitertia ratio
by: Antonio Armisén
Published: (2008-12-01)

Aug
by: Tan, Daryl Christian Guanjie, et al.
Published: (2014)

A CONSTRUÃÃO DO SIGNIFICADO NAS ORGANIZAÃÃES
by: YÃ¡ra LÃºcia Mazziotti Bulgacov, et al.
Published: (2007-12-01)

Research summary : Aug 1980 - Aug 1981 /
by: Asian Institute of Technology. Division of Human Settlements Development
Published: ([19-)

REPUTAÃÃO CORPORATIVA: MENSURAÃÃO E ANÃLISE DE MAPAS PERCEPTUAIS â UM ESTUDO EMPÃRICO NA INDÃSTRIA AUTOMOBILÃSTICA BRASILEIRA
by: Miguel MaurÃcio Isoni, et al.
Published: (2004-12-01)

AVALIAÃÃO DO EMPREGO DA TÃCNICA DE ANÃLISE DISCRIMINANTE EM TESES E DISSERTAÃÃES DE ALGUMAS INSTITUIÃÃES DE ENSINO SUPERIOR
by: Carolina Monari, et al.
Published: (2010-03-01)

PODEM AS PERCEPÃÃES DE PREÃO INFLUENCIAR A SATISFAÃÃO DO CONSUMIDOR?
by: Samanta Rounti, et al.
Published: (2007-04-01)

GESTÃO ESTRATÃGICA HOSPITALAR: APLICAÃÃO DE CUSTOS NA SAÃDE
by: Cyntia Aparecida de Amorim, et al.
Published: (2009-12-01)